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Abstract. 
 
Genomic disorders are a clinically diverse group of conditions caused by gain, 
loss or re-orientation of a genomic region containing dosage-sensitive genes. One 
class of genomic disorder is caused by hemizygous deletions resulting in 
haploinsufficiency of a single or, more usually, several genes. For example, the 
heterozygous contiguous gene deletion on chromosome 22q11.2 causing DiGeorge 
syndrome involves at least 20-30 genes. Determining how copy number variation 
(CNV) affects human variation and contributes to the aetiology and progression of 
various genomic disorders represent important questions for the future. Here, I will 
discuss the functional significance of one form of CNV, haploinsufficiency (ie. loss of 
a gene copy), of DNA damage response components and its association with certain 
genomic disorders. There is increasing evidence that haploinsufficency for certain 
genes encoding key players in the cells response to DNA damage has a functional 
impact, particularly those of the Ataxia Telangiectasia and Rad3-related (ATR)-
pathway. I will review this evidence and present examples of some well known 
clinically similar genomic disorders that have recently been shown to be defective in 
the ATR-dependent DNA damage response. Finally, I will discuss the potential 
implications of a haploinsufficiency-induced defective DNA damage response for the 
clinical management of certain human genomic disorders. 
 
1. Introduction. 
 
It has long been appreciated that changes in gene copy number are associated 
with phenotypes in humans. Perhaps the most well know example of this is the 
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trisomy 21 causative of Down syndrome. Here, increased expression of the genes on 
chromosome 21 results directly or indirectly in a clinically heterogeneous disorder 
incorporating cognitive impairment, facial dysmorphology, growth retardation, cancer 
predisposition, microcephaly, heart and skeletal abnormalities [1]. Interestingly, it 
was recently shown that CNV is in fact a common genetic trait in clinically unaffected 
or ‘normal’ individuals [2]. Indeed, the first complete genomic sequence from an 
individual, the so-called ‘Venter genome’ yielded a surprising level of CNV, 
highlighting the plasticity of the human genome [3]. The phenomenal recent 
revolution in the sensitivity and widespread usage of array-based Comparative 
Genomic Hybridization (array-CGH) techniques has led to CNV being described as 
the ‘Breakthough of the Year’ by the journal Science [4]. The widespread use of a-
CGH has facilitated the description of several novel genomic disorders and aided in 
the detailed genetic characterisation of known genomic disorders. A persistent 
challenge to clinical geneticists and researchers is to unravel exactly how changes in 
CNV of specific genes or various combinations of genes can impact on normal 
development. These issues have recently been extensively reviewed elsewhere and the 
reader is directed to these sources for an overview of a-CGH technology and its 
applications [5-12]. Here, I will discuss the potential role of haploinsufficiency of 
DNA damage response components in genomic disorders. Contiguous gene deletion 
disorders represent a clinically diverse group of human genomic disorders caused by 
distinct heterozygous chromosomal deletions usually involving several genes [5,13]. 
It is assumed that the various clinical manifestations of different genomic disorders 
arise from the combined impact of haploinsufficiency of multiple genes [14]. It is 
likely that there are critical genes or pathways sensitive to haploinsufficiency either 
alone or when combined with haploinsufficiency of other genes. There is increasing 
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evidence from both human and murine studies suggestive of a cellular impact of 
haploinsufficiency of genes that control different aspects of the response to DNA 
damage. Since our genomes are constantly exposed to exogenously-derived (eg. UV 
radiation) and endogenously-derived (eg. metabolically generated reactive oxygen 
species) DNA damaging agents, an impaired ability to detect and/or respond 
appropriately to these threats can impact on the maintenance of genetic stability. 
There are many examples of human Mendelian disorders defective in the repair of or 
response to DNA damage [15]. The importance of these pathways is demonstrated by 
the increase in cancer predisposition and developmental abnormalities associated with 
these conditions [15]. An important DNA damage response (DDR) pathway that 
appears to be affected by haploinsufficiency is the ATR-dependent DDR (ATR-
DDR). 
 
2. The ATR-dependent DNA damage response (ATR-DDR). 
 
The DDR can be divided into DNA repair processes and signal transduction 
processes that sense DNA damage and co-ordinate the appropriate response such as 
cell cycle checkpoint activation, DNA repair and/or apoptosis. Two phosphoinositol-
3-kinase-like protein kinases (PIKK) co-ordinate the signal transduction response to 
DNA damage in mammalian cells [16-18]. Ataxia Telangiectasia Mutated (ATM) is 
activated following DNA double strand breaks (DSBs) whilst a related kinase, Ataxia 
Telangiectasia and Rad3-related (ATR), responds to single stranded regions of DNA. 
Single stranded DNA (ssDNA) can occur as an intermediate during the activity of 
several excision-mediated repair pathways (nucleotide excision repair and base 
excision repair), during uncoupling of the transcriptional machinery from its DNA 
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template or similarly following stalling of the DNA replication machinery at DNA 
lesions or single strand breaks. Following the exposure of ssDNA it is quickly coated 
by RPA a heterotrimeric protein complex (RPA1-3) that plays a role in many aspects 
of DNA metabolism (eg. replication, repair, transcription). ATR is recruited to the 
ssDNA via its binding partner ATRIP (ATR Interacting Protein) [19,20]. 
Topoisomerase binding protein 1 (TopBP1) appears to be required for optimal ATR 
kinase activity [21]. Phosphorylation of the histone H2A variant H2AX on Ser-139 
(called γ-H2AX) is one of the earliest detectable PIKK-dependent responses to DNA 
damage and is required for the retention of additional damage response proteins at the 
damage site [22-24]. The Mre11/Rad50/NBS1 complex, the Rad17/Rfc2-5 and 
Rad9/Rad1/Hus1 complexes are recruited to the site of damage independently of 
ATR/ATRIP and are also phosphorylated by ATR [25,26]. Retention of these 
complexes facilitates ATR’s ability to phosphorylate downstream substrates including 
Brca1, p53 and its effector kinase Chk1 [15].  
 
There is a large amount of functional overlap between ATM and ATR. In fact, 
both kinase’s phosphorylate mainly the same substrates in response to DNA damage 
(eg. Mre11/Rad50/NBS1 complex, p53, Brca1). DSBs can undergo exonucleolytic 
resection generating ssDNA overhangs, hence generating an ATR activating substrate 
[27]. Conversely, ssDNA generated at stalled replication forks can collapse producing 
overt DSBs, hence generating an ATM activating substrate [28]. Nevertheless, 
congenital defects in ATM and ATR are associated with clinically distinct human 
disorders. Mutations in ATM cause Ataxia telangiectasia, a progressive degenerative 
neurological disorder characterised by ataxia and lymphoid malignancy predisposition 
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[29,30]. Mutations in ATR result in Seckel syndrome a disorder characterised by 
microcephaly and growth retardation [31,32].  
 
3. ATR and genomic stability. 
 
ATR is required to maintain genomic stability. Whilst it has a role in the 
stabilisation of stalled replication forks, the absence of ATR results in a very specific 
type of genomic instability, namely DNA Fragile Site expression. DNA Fragile Sites 
(DFS) are large (>100Kb) distinct genomic regions that exhibit breaks under 
conditions of replicative ‘stress’ [33,34]. Such stresses can be induced in the 
laboratory using DNA replication inhibitors such as aphidicolin or by folate 
deficiency, which can indirectly impact on the availability of dNTP’s. There are about 
75-80 DFS throughout the human genome but it is not really clear why DFS are so 
unstable. Most tend to be relatively AT-rich and contain more areas of flexibility that 
non-fragile site regions. Studies on the replication timing of certain fragile sites 
(FRA3B, FRA7H, FRAXA on chromosome 3, 7 and X respectively) indicate that 
they are replicated very slowly [33]. DFS are ‘hot spots’ for sister chromatid 
exchanges (SCE’s) and are also thought to play a role in gene amplification events via 
a breakage-fusion-bridge cycle [33]. Breakage at or ‘expression of’ DFS is associated 
with many cancers. For example, the FHIT tumour suppressor gene spans the DFS 
FRA3B [35]. This gene is often re-arranged or partially deleted in a wide range of 
tumours (lung, ovarian, breast, esophageal) [36].  Pioneering work by the Glover 
laboratory identified ATR as the first protein required to mediate DFS stability [37]. 
Subsequently, several other proteins have been implicated in maintaining DFS 
stability including the Brca1, SMC1, WRN helicase, Chk1 and the Fanconi anaemia 
 7
pathway components FANC-A, FANC-B and FANC-D2 [33,38-41]. Interestingly, 
most of these proteins are known direct ATR substrates.  
 
4. Seckel syndrome: an ATR-pathway defective disorder. 
 
 Seckel syndrome, originally described as ‘Bird headed Dwarfism’ in a 
1960 monograph by Dr. Helmut Seckel, is a disorder characterised by severe 
microcephaly, isolated skeletal abnormalities (clinodactyly, thoracic kyphosis, ivory 
epiphesis) and a dramatic proportionate primordial dwarfism [42]. Microcephaly is a 
clinical term describing a reduction in occipitofrontal (or head) circumference greater 
than 3 standard deviations (-3 s.d.) below the age-related mean. This reduced head 
circumference is a consequence of premature closure and fusion of the cranial sutures 
reflecting the underlying reduction in brain volume. The aetiology of microcephaly is 
complex. It can occur in the context of genetic (e.g. syndromal) or non-genetic (e.g. 
intrauterine infection) situations. Microcephaly is particularly pronounced in Seckel 
syndrome [31,42,43]. The first genetic defect associated with Seckel syndrome was 
described by in 2003. A single synonymous hypomorphic mutation in ATR was 
identified in five affected individuals in two consanguineous Pakistani families [31]. 
The mutation (A21201G) was shown to adversely impact on splicing resulting in 
dramatically reduced ATR expression in cells derived from the affected patients. 
Gene targeting of ATR in the murine system results in early embryonic lethality 
[44,45]. Hence, these ATR-defective Seckel syndrome cells (ATR-S) proved a useful 
tractable model to investigate ATR-pathway function in the mammalian setting. ATR-
S cells exhibited a diminished ability to phosphorylate ATR substrates following 
DNA damage-induced ATR-pathway activation (e.g. γH2AX formation and p53-
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serine-15 phosphorylation) as well as defective cell cycle checkpoint arrest and 
increased DFS expression [31,46,47].  
 
 Seckel syndrome is known to be genetically heterogeneous [43,46,48-50]. 
Interestingly, Alderton et al showed that several unrelated non-ATR mutated Seckel 
syndrome cell lines all exhibited defective ATR-pathway function (e.g. failure of 
ATR-dependent G2-M cell cycle checkpoint arrest) [46]. Hence, in agreement with 
the known genetic heterogeneity of this condition, whilst not all Seckel syndrome 
cases are caused by mutations in ATR itself, interestingly, all Seckel syndrome cell 
lines (ATR-S and non-ATR-S) exhibit compromised ATR-pathway function [46]. A 
further interesting cellular feature of ATR-pathway defective Seckel cells is 
supernumerary centrosomes in 10-20% of mitotic cells [46]. A normal mitotic cell 
must only have two centrosomes that nucleate the microtubuelle spindles facilitating 
transfer of an equal and identical chromosome complement to the daughter cells 
[51,52].  The molecular aetiology of supernumerary mitotic centrosomes in Seckel 
syndrome cells is currently unclear. Centrosome orientation is fundamental for 
determining symmetric and asymmetric stem cell division in the embryonic 
neuroepithelium, an essential process for normal brain development [53-55].  Hence, 
this cellular feature may be a relevant contributor to the severe microcephaly 
characteristic of Seckel syndrome. Recently, the second genetic defect associated with 
Seckel syndrome was described. Mutations in pericentrin (PCNT2)/kendrin which 
encodes a structural centrosomal protein, were identified in several Seckel syndrome 
patients all of which exhibited defective ATR-pathway function [56]. This exciting 
finding further illustrates a functional link between the DDR, the cell cycle machinery 
and the centrosome. Furthermore, mutations in PCNT2 were also recently found in 
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several microcephalic osteodysplastic primordial dwarfism type II (MOPD II) patients 
[57,58]. Whether PCNT2-mutated Seckel syndrome and MOPD II represent distinct 
disorders or allelic variants of the same condition remains an open question. 
 
5. Other disorders that exhibit compromised ATR-pathway function. 
 
 Compromised ATR-pathway function does not appear to be uniquely 
associated with Seckel syndrome. Several other known DDR disorders have been 
shown to be defective in aspects of ATR-pathway activity, particularly cell cycle 
checkpoint activation. Interestingly, whilst these disorders are all characterised by a 
distinct set of clinical features there is significant clinical overlap with Seckel 
syndrome, particularly concerning the developmental abnormalities such as 
microcephaly and growth retardation. 
 
5.1 Nijmegen breakage syndrome (NBS). 
 
NBS is caused by hypomorphic mutations in the Nbs1 component of the 
Mre11/Rad50/NBS (MRN) complex [59,60]. The MRN complex plays a central role 
in ATM signalling where it is thought to recruit ATM to the DSB and also facilitate 
its ability to phosphorylate substrates such as p53 and Chk2 [61]. In fact, all the 
components of this complex are ATM substrates. Historically, NBS has been 
described as an A-T-like disorder as cell lines from both conditions exhibit radio-
sensitivity and similar cell cycle checkpoint defects in response to DSBs. But, NBS1 
is also an ATR substrate and NBS patients exhibit microcephlay and growth 
retardation, clinical features associated with Seckel syndrome and not A-T.  Recently, 
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NBS cells were shown to be compromised for ATR-dependent checkpoint activation 
and other aspects of ATR-pathway function [26]. Therefore, NBS represents a human 
condition defective in elements of both ATM and ATR-pathway activity. 
 
5.2 Fanconi anaemia (FA). 
 
FA, is a genetically heterogeneous condition characterised by a progressive 
aplastic anaemia, skeletal abnormalities, microcephaly and lymphoid malignancy. FA 
is caused by mutations in different genes whose products co-ordinately function in the 
cellular response to DNA cross-links [62,63]. Several of these genes encode products 
that together mediate the monoubiquitylation and activation of the FANC-D2 protein 
in response to DNA damage, particularly during S phase [62]. ATR and NBS1 have 
been shown to be required for this specific modification [64-66]. In fact, ATR-S and 
NBS patient-derived cell lines fail to monoubiquitylate FANC-D2 following 
treatment with replication fork inhibitors [26]. In addition to undergoing 
monoubiquitylation, FANCD2 has been shown to be phosphorylated by ATM and 
ATR further highlighting the over-lap between these DDR pathways [26,64,67].  
 
5.3 MCPH1-dependent Primary Microcephaly. 
 
 Autosomal recessive Primary Microcephaly, clinically characterised by the 
presence of a severe microcephaly in the absence of other overt clinical features, is a 
genetically heterogeneous condition composed of six distinct genetic 
complementation groups. To date, mutations in four genes, all of which encode 
centrosomal proteins, have been described for this disorder (MCPH1, ASPM, 
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CDK5/RAP2, CENPJ) [55,68-71]. Microcephalin (MCPH1), the first Primary 
Microcephaly gene identified encodes a BRCT-containing product that has been 
implicated in the response to DSBs [72,73]. Importantly, work using MCPH1-patient 
derived cell lines with hypomorphic mutations in MCPH1 indicated that these cells 
are defective in ATR-dependent checkpoint activation and also exhibit supernumerary 
mitotic centrosomes [74]. Furthermore, MCPH1 was shown to interact with Chk1, a 
substrate and downstream effector of ATR [74]. 
 
6. The impact of ATR haploinsufficiency: Murine studies. 
 
All of the disorders described so far that collectively exhibit defective ATR-
pathway function are all caused by gene mutations inherited in an autosomal recessive 
manner. As mentioned earlier, a knockout mouse model for ATR does not exist due to 
early embryonic lethality of ATR-/- blastocysts [44,45]. Whilst ATR+/- animals are 
viable, re-evaluation of this murine work suggests that the ATR-DDR pathway is 
sensitive to gene copy number variation. Firstly, ATR+/- mice are not born at the 
expected Mendelian frequency suggesting a requirement for a full diploid 
complement of ATR protein during normal development [75]. Furthermore, decreased 
survival and increased tumour incidence was recorded in the ATR+/- animals 
compared to their ATR+/+ counterparts [75]. This is distinct to that of ATM+/- embryos 
and mice. Heterozygous mutations in ATR have been observed in microsatellite 
unstable human colorectal carcinomas further suggesting that ATR haploinsufficiency 
may play a role in tumourigenesis [76]. In fact, it has been suggested that ATR acts as 
a haploinsufficient tumour suppressor under certain circumstances. Fang and 
colleagues showed that ATR+/- mice when crossed into a mismatch repair defective 
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(Mlh1-/-) background (generating ATR+/-/Mlh1-/-) were highly susceptible to 
embryonic lethality and premature tumour development [77]. 
 
7. The impact of ATR haploinsufficiency: Human studies, including the 
association of ATR+/- with a genomic disorder. 
 
Fang and colleagues also showed that haploinsufficiency of ATR in human 
cells results in a clear DDR-defective phenotype [77]. Following gene targeting of 
ATR in the human HCT116 colorectal carcinoma cell system, they found a 
significantly increased expression of DFS as well as other gross chromosomal 
rearrangements and amplifications. Furthermore, these ATR+/- cells exhibited 
diminished ATR-mediated phosphorylation of its effector kinase Chk1. 
 
Work from de Ru and colleagues along with that of O’Driscoll and colleagues 
has provided evidence for a cellular impact of ATR haploinsufficiency associated 
with a human genomic disorder [78,79]. Blepharophimosis-ptosis-epicanthus inversus 
syndrome (BPES) is a disorder characterised by a reduction in the dimensions of the 
palpebral fissues or eye sockets (blepharophimosis), drooping eyelids (ptosis) and 
inverted skin folds originating from the lower eyelids (epicanthus inversus) [80]. A 
variant of this disorder is also associated with ovarian failure and female infertility 
[81]. This disorder is caused by autosomal dominant mutations in or heterozygous 
deletion of FOXL2, a putative forkhead transcription factor [80]. In a review of the 
literature, de Ru and colleagues noted that most of the BPES patients with a 
cytologically detectable deletion or a microdeletion on chromosome 3q, where 
FOXL2 resides, also exhibited microcephaly and short stature [78]. These are clinical 
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features not typically associated with ‘classical’ BPES. Indeed, it had been previously 
proposed that a putative gene for microcephaly was located close to the BPES-
causative gene on chromosome 3q (reviewed in [78]). De Rue and colleagues mapped 
the heterozygous deletion in one such BPES patient with microcephaly and short 
stature. They found that this patient was haploinsufficient for both FOXL2 and ATR at 
the genomic level. They suggested that the haploinsufficiency of ATR may be 
responsible for the microcephaly and short stature observed in this patient based on 
the occurrence of these clinical features in ATR-defective Seckel syndrome [78]. In a 
complementary study, O’Driscoll and colleagues subsequently showed that cells from 
this BPES-ATR+/- patient exhibited similar cellular defects to ATR-S cells [79]. These 
cells failed to show significant γH2AX formation and Chk1 phosphorylation 
following replication fork stalling. They also exhibited a similar ATR-dependent G2-
M cell cycle checkpoint defect to ATR-S cells. Importantly, this phenotype was 
corrected following over-expression of ATR in the BPES-ATR+/- cells. This study 
reinforced that fact that haploinsufficiency of ATR has a functional impact in human 
cells but furthermore, that haploinsufficiency of ATR is associated with a human 
genomic disorder that exhibits microcephaly and short stature [79].    
 
7. Haploinsufficiency of ATR-pathway components in other genomic disorders. 
 
Work from Lam and colleagues using tissue-specific conditional knockdown 
in mice of Chk1, an important effector kinase and substrate of ATR, showed that 
Chk1 haploinsufficiency enhances mammary tumourigenesis [82]. This work 
suggested that an ATR-pathway component and not just ATR itself is sensitive to 
haploinsufficiency. Following the cellular characterisation of BPES- ATR+/-, working 
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on the presumption that the ATR-pathway as a whole is sensitive to a reduced gene 
copy number, O’Driscoll and colleagues examined ATR-pathway function in other 
human genomic disorders whose causative genomic deletions were known to result in 
haploinsufficiency of various ATR-pathway components [79]. 
 
7.1 Isolated Lissencephaly Sequence (ILS) and Miller-Dieker lissencephlay 
syndrome (MDLS). 
 
 Normal human brain development involves a rapid and sustained cellular 
proliferation originating from the rostral end of the foetal neural tube. Cerebral 
cortical development is achieved via a highly regulated sequence of neuroprogenitor 
cell division, migration and differentiation. Platelet-activating factor acetylhydrolase, 
isoform B1 (PAHFAH1B1/Lis1), located on human chromosome 17p13.3, encodes a 
protein, Lissencephaly 1 (Lis1), which plays a central role in neuronal migration from 
the neuroepithelial stem cell layer during embryonic brain development [83-85]. 
Mutations in or heterozygous deletions of PAHFAH1B1/ Lis1 alone causes Isolated 
Lissencephly Sequence (ILS), a disorder characterised by reduced neuronal migration 
resulting in a cortical surface without significant invaginations, effectively a "smooth 
brain" (lissencephaly) (Figure 1). Larger deletions identified in some ILS patients 
confer a more severe grade of lissencephaly associated with additional craniofacial 
abnormalities (ILS+) (Figure 1). Even larger deletions extending telomerically from 
the PAHFAH1B1/Lis1 gene are associated with Miller-Dieker Lissencephaly 
Syndrome (MDLS), which is characterised by the most severe grade of lissencephaly, 
craniofacial abnormalities, microcephaly and growth retardation (Figure 1) [14,86]. 
Unlike ILS patients, ILS+ patients and all MDLS patients are haploinsufficient for 
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RPA1, the largest subunit of the Replication Protein A complex (Figure 1) [86]. As 
described previously, this complex coats ssDNA generated for example at a stalled 
replication fork allowing the recruitment and ultimate activation of ATR [19]. Similar 
to what was observed using BPES-ATR+/- cells, cell lines from ILS+ and MDLS 
patients collectively exhibited compromised ATR-pathway function [79]. 
Furthermore, these cellular defects could be complemented following over-expression 
of RPA1 in these cells. ILS patient cell lines with heterozygous deletions in 
PAHFAH1B1/ Lis1 only, by contrast, exhibited a functional ATR-pathway response 
(Figure 1). Therefore, ILS+ and MDLS represent two further human genomic 
disorders with a clinical overlap with ATR-S that also exhibit compromised ATR-
pathway function at the cellular level [79]. 
 
7.2 Williams-Beuren syndrome (WBS) 
 
 WBS is caused by a hemizygous sub-microscopic deletion of 1.55-1.84Mbp 
on chromosome 7q11.23 encompassing around 25-30 genes. The clinical presentation 
of this condition is multifaceted including craniofacial, endocrinological and 
cardiovascular abnormalities along with microcephaly and growth retardation [87,88]. 
One of the genes heterozygously deleted in WBS is ELN, which encodes elastin, a key 
structural component of vascular tissues. A characteristic cardiovascular abnormality 
of WBS, supravalvular aortic stenosis (narrowing of the ascending aorta), is thought 
to specifically derive from haploinsufficieny of ELN [89]. WBS patients are also 
haploinsufficient for RFC2 a gene that encodes a component of the Replication Factor 
C (RFC) complex that plays a fundamental role during DNA replication loading 
PCNA onto chromatin facilitating DNA polymerase action [90]. RFC2 is also a 
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component of the Rad17-RFC2-5 complex that is known to function in the DDR [91-
94]. In fact, Rad17 is phosphorylated by ATM and ATR following DNA damage. 
Interestingly, a yeast stain (S. cerevisae) with a hypomorphic mutation in Rfc2 fails to 
activate cell cycle arrest following DNA damage suggesting that the RFC complex 
and specifically RFC2 plays a direct role in the DDR [95]. O’Driscoll and colleagues 
also showed that WBS patient-derived cell lines exhibit a defective ATR-dependent 
DDR that could be complemented following re-introduction of RFC2 into these cells 
[79]. Therefore, WBS represents another genomic disorder that exhibits defective 
ATR-pathway activity wherein microcephaly and growth retardation are included in 
its clinical spectrum [79]. 
 
 Of course for all of the genomic disorders discussed above that exhibit a 
defective ATR-dependent DDR associated with microcephaly and short stature, the 
occurrence of this specific DDR defect with these particular clinical features is 
associative. This association, albeit strong, remains an association only, hence more 
work using complementary systems such as gene targeting or tissue-specific 
knockdown in the murine system will be required to definitively prove the link 
between ATR-pathway dysfunction and these developmental abnormalities. 
 
8. Haploinsufficiency of other DDR components. 
 
Increasing evidence from murine gene targeting studies suggests that 
haploinsufficiency of various components of a diverse distinct range DDR pathways 
and not just ATR or ATR-pathway components have a functional impact on 
maintaining genomic stability. For example, haploinsufficiency of various 
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components of the mitotic spindle checkpoint such BubR1 or MAD2 are associated 
with aberrant chromosome segregation and aneuploidy in mice [96,97]. Recently, 
haploinsufficiency of another mitotic spindle checkpoint component, Mad1, has been 
shown to be associated with aneuploidy and increased constitutive tumour incidence 
in Mad1+/- mice compared to their wild-type (Mad1+/+) littermates [98]. Homologous 
recombination (HR) is an error-free DSB repair pathway used by mammalian cells 
when a homologous sister chromatid is available as a template for DNA repair (S- and 
G2-phases of the cell cycle) [99]. Haploinsufficiency of multiple genes whose 
products function in HR results in compromised genomic stability. Specific examples 
include Brca1+/-, Xrcc2+/-, Xrcc3+/-, Rad51b+/- and Rad51d+/- mice, all of which 
present with recombination deficiency, increased chromosomal aberrations and 
centrosomal fragmentation [100-105]. The Mus81-Eme1 complex functions as a 
structure specific endonuclease that plays a role in resolving stalling replication forks, 
3’-orientated DNA flaps/overhangs and nicked HR intermediates [106]. 
Haploinsufficiency of both components of the structure specific endonuclease Mus81-
Eme1 results in increased chromosomal aberrations and a re-replication phenotype in 
human and murine cells [107]. Poly(ADP-ribose) polymerase-1 (PARP-1) catalyzes 
the covalent attachment of long branched poly(ADP-ribose) polymers onto a diverse 
set of target proteins (including itself), using NAD+ as its substrate. Attachment of 
these negatively charged polymers changes the biological activity and properties of 
the target proteins. PARP1 plays an important role in sensing single stranded breaks 
in DNA [108-110]. The level of PARP activity is sensitive to PARP-1 gene dosage 
[111]. Interestingly, PARP1-/+ mouse embryonic fibroblasts were shown to exhibit 
increased supernumerary centrosomes relative to their PARP+/+ counterparts [111]. 
Furthermore, haploinsufficiency of the histone H2A sub-family member H2AX, a 
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known ATM and ATR substrate, has been shown to compromise genomic integrity, 
impact on the normal response to DNA damage and enhance tumour susceptibility in 
the absence of p53 in mice [112].  
 
9. Implications of haploinsufficiency of DDR components in human genomic 
disorders. 
 
Murine gene targeting studies have proved invaluable in identifying DDR 
pathways that are sensitive to haploinsufficiency (e.g. the spindle checkpoint and 
HR). It is likely that haploinsufficiency of these pathways potentially contribute/will 
contribute to the clinical features of known and/or novel genomic disorders. A major 
consequence of compromised DDR is increased genomic instability and cancer 
predisposition (reviewed in [15]). Additionally, since DNA damaging agents are the 
cornerstone of clinically utilised therapeutic approaches for cancer, individuals with 
compromised DDR are hypersensitive to such treatments. This has been observed in 
Ataxia telangiectasia, Nijmegen breakage syndrome, LIG4 syndrome and Fanconi 
anaemia patients, some of which have fatally over-responded to standard radio- and/or 
chemotherapy regimens in the past (reviewed in [113]). Since increased life 
expectancy due to improved medical supervision is now a feature of many genomic 
disorders, a potentially defective DDR may become more important from the 
perspective of tumour development and treatment. This could be particularly relevant 
for genomic disorders with compromised ATR-pathway function. Whilst it is not 
clear whether conditions such as BPES-ATR+/-, MDLS and WBS represent tumour-
predisposition conditions, it is clear that they do exhibit a defective ATR-dependent 
DDR [79]. Provocatively, isolated reports of malignancy in these disorders, 
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particularly in WBS exit [114-117]. Whether a compromised ATR-dependent DDR 
has a role here is currently unclear although worthy of deeper investigation. 
 
In conclusion, plasticity of the human genome is reflected in the high level of 
CNV observed in clinically normal individuals. Nevertheless, CNV is associated with 
many pathological conditions in humans. Gene-targeting studies in mice have shown 
that one form of CNV, namely haploinsufficiency, of certain DDR-pathway 
components is associated with compromised genomic stability. Haploinsufficiency of 
ATR, or some of its pathway components confers a similar DDR defects to that of 
ATR-pathway defective Seckel syndrome cell lines. Furthermore, haploinsufficiency 
of ATR, RPA1 and RFC2 are associated with several human genomic disorders that 
exhibit microcephaly and growth retardation. Haploinsufficiency of DDR pathway 
components are likely to contribute to the clinical features of many genomic 
disorders. This will have implications for the clinical management and treatment of 
these conditions.
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and head size.
Functional ATR-DDR.
RPA-/+ Growth retardation
and microcephaly.
Defective ATR-DDR
Figure 1. A). Chromosome 17 karyotype from a normal and MDLS individual. B). A view of a single 
chromatid of chromosome 17p13.3 showing the order of the genes in this region from the centromere 
(Cen) to the telomere (Tel). The dotted lines denote the hemizygous deletions of various sizes associated 
with respective patients listed on the left hand side. Con-MR is a patient with a telomeric deletion. This 
patient exhibits mental retardation but normal stature and head circumference. ILS represents an Isolated 
Lissencephaly Sequence patient deleted for PAFAH1B1/Lis1. ILS+ denotes Isolated Lissencephaly 
Sequence patients with increasing deletions telomeric from PAFAH1B1/Lis1. MDLS represents Miller-
Dieker Lissencephaly. 
 21
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Disorder Mutant gene ATR-dependent cellular features
Seckel syndrome ATR, PCNT2 and unknown Defective ATR-dependent G2-M arrest, supernumerary mitotic centrosomes,
DFS expression
Nijmegen breakage syndome NBS1 Defective ATR-dependent G2-M arrest
Fanconi anaemia FANC-A,B,C,D1,D2,E,F,G,H,M,J Defective ATR-dependent G2-M arrest, DFS expression
MCPH1-dependent Primary
Microcephaly MCPH1 Defective ATR-dependent G2-M arrest, supernumerary mitotic centrosomes
Table 1. Mendelian disorders that exhibit microcephaly and growth retardation associated with defective  
ATR-pathway function. 
Disorder Chromosome Deletion        ATR-pathway ATR-dependent 
component                  cellular features
BPES-ATR+/- 3q23 ATR Defective ATR-dependent γH2AX format ion, Chk1
phosphorylation and G2-M arrest
Isolated Lissencephlay 
Sequence 17p13.3 RPA1 Defective ATR-dependent γH2AX format ion, Chk1
phosphorylation and G2-M arrest
Miller-Dieker Lissencephaly 17p13.3 RPA1 Defective ATR-dependent γH2AX format ion, Chk1
Syndrome phosphorylation and G2-M arrest
Williams-Beuren Syndrome 7q11.23 RFC2 Defective ATR-dependent G2-M arrest
Table 2. Genomic disorders that exhibit microcephaly and growth retardation associated with with hemizygous 
deletions of ATR pathway components. 
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Web Resources 
 
Online Mendelian Inheritance in Man, (http://www.ncbi.nlm.nih.gov/Omim), 
for reviews of the specific genes and all of the disorders described here. 
 
DECIPHER,(https://decipher.sanger.ac.uk/), a database collating multiple 
genomic imbalances and their associated clinical features in human genomic 
disorders. 
 
EUCARUCA, (http://agserver01.azn.nl:8080/ecaruca/whatisEc.jsp), a 
database of cytogenetic and clinical data of rare chromosomal aberrations from all 
centres that are member of the European Cytogeneticists Association (ECA). 
 
Database of Genomic Variants, (http://projects.tcag.ca/variation/ ), a database 
listing a comprehensive summary of structural variation in the human genome. 
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